Overview

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or a mismatched related donor, can help to control Hodgkin's disease. The safety of the treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Antilymphocyte Serum
Fludarabine
Fludarabine phosphate
Gemcitabine
Lenograstim
Melphalan
Methotrexate
Tacrolimus
Thymoglobulin
Vidarabine